AEOLUS PHARMACEUTICALS, INC.: 10-Q filed 2016-05-16

Name: AEOLUS PHARMACEUTICALS, INC.: 10-Q filed 2016-05-16
Creator: AEOLUS PHARMACEUTICALS, INC.

What AEOLUS PHARMACEUTICALS, INC. reported in its quarterly report filed 2016-05-16 (fiscal Q2 2016): 24 published measures, 70 facts as tagged in accession 0001102624-16-002806.

This filing

Form: 10-Q (quarterly report)
Filed: 2016-05-16
Fiscal period: fiscal Q2 2016
Accession: 0001102624-16-002806 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AEOLUS PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2016-03-31	6,260,000	USD
At 2015-09-30	1,777,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2016-03-31	1,236,000	USD
At 2015-09-30	2,622,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2016-03-31	5,024,000	USD
At 2015-09-30	-845,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2016-03-31	4,509,000	USD
At 2015-09-30	94,000	USD
At 2015-03-31	248,000	USD
At 2014-09-30	1,517,000	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	-629,000	USD	91
2015-10-01 to 2016-03-31	-1,662,000	USD	183
2015-01-01 to 2015-03-31	-712,000	USD	90
2014-10-01 to 2015-03-31	-1,410,000	USD	182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2015-10-01 to 2016-03-31	-1,755,000	USD	183
2014-10-01 to 2015-03-31	-1,269,000	USD	182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2015-10-01 to 2016-03-31	6,170,000	USD	183
2014-10-01 to 2015-03-31	0	USD	182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2016-03-31	-188,293,000	USD
At 2015-09-30	-186,630,000	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	151,560	shares	91
2015-10-01 to 2016-03-31	145,466	shares	183
2015-01-01 to 2015-03-31	135,850	shares	90
2014-10-01 to 2015-03-31	135,850	shares	182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	151,560	shares	91
2015-10-01 to 2016-03-31	145,466	shares	183
2015-01-01 to 2015-03-31	135,850	shares	90
2014-10-01 to 2015-03-31	135,850	shares	182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	-0.02	USD/shares	91
2015-10-01 to 2016-03-31	-0.03	USD/shares	183
2015-01-01 to 2015-03-31	-0.01	USD/shares	90
2014-10-01 to 2015-03-31	-0.01	USD/shares	182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	-0.02	USD/shares	91
2015-10-01 to 2016-03-31	-0.03	USD/shares	183
2015-01-01 to 2015-03-31	-0.01	USD/shares	90
2014-10-01 to 2015-03-31	-0.01	USD/shares	182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2015-10-01 to 2016-03-31	74,000	USD	183
2014-10-01 to 2015-03-31	259,000	USD	182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	-629,000	USD	91
2015-10-01 to 2016-03-31	-1,377,000	USD	183
2015-01-01 to 2015-03-31	-712,000	USD	90
2014-10-01 to 2015-03-31	-1,410,000	USD	182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2016-03-31	6,228,000	USD
At 2015-09-30	1,745,000	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	0	USD	91
2015-10-01 to 2016-03-31	285,000	USD	183
2015-01-01 to 2015-03-31	0	USD	90
2014-10-01 to 2015-03-31	0	USD	182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2016-03-31	1,236,000	USD
At 2015-09-30	2,622,000	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2016-03-31	1,366,000	USD
At 2015-09-30	1,585,000	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	501,000	USD	91
2015-10-01 to 2016-03-31	993,000	USD	183
2015-01-01 to 2015-03-31	1,297,000	USD	90
2014-10-01 to 2015-03-31	2,270,000	USD	182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2016-03-31	151,559,745	shares
At 2015-09-30	135,930,068	shares

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2016-03-31	156,000	USD
At 2015-09-30	45,000	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	-2,535,000	USD	91
2015-10-01 to 2016-03-31	-4,148,000	USD	183
2015-01-01 to 2015-03-31	-712,000	USD	90
2014-10-01 to 2015-03-31	-1,410,000	USD	182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2016-01-01 to 2016-03-31	693,000	USD	91
2015-10-01 to 2016-03-31	1,254,000	USD	183
2015-01-01 to 2015-03-31	604,000	USD	90
2014-10-01 to 2015-03-31	1,254,000	USD	182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2015-10-01 to 2016-03-31	-219,000	USD	183
2014-10-01 to 2015-03-31	248,000	USD	182

Inspect the source

Entity: AEOLUS PHARMACEUTICALS, INC. / CIK 0001261734
Captured: 2026-09-23 02:48 UTC
SEC response SHA-256: 13496f8521e85309f968eb406ca1d2937f174c6b48d9ce05e9c6e27a6515d993

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001261734.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))